NCT01581294Recruiting
The Norwegian Antirheumatic Drug Register
Long-term Safety and Effectiveness of Disease Modifying Therapies in Inflammatory Arthropathies: a Multicentre, Phase IV, Longitudinal Observational Study
Source: ClinicalTrials.gov · Last updated 23 Aug 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease activity, health related quality of life, function and joint damage, and to study the long-term safety of such treatment. Other objectives include the assessment of cost-effectiveness of treatment, to identify and and validate clinical, genetic and immunological predictors of efficacy and adverse events, to assess the impact of treatment with biological DMARDs on work participation and work productivity, to investigate different strategies for use of biological DMARDs, to assess the performance of different outcome measures, and to ensure a systematic and timely follow-up of patients treated with biological DMARDs.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 15000 (estimated)
- First submitted
- 18 Apr 2012
- Start date
- Apr 2012
- Primary completion date
- Dec 2050
- Lead sponsor
- Diakonhjemmet Hospital
- NCT number
- NCT01581294
What you commit to
- Study type: Observational
- Planned participants: 15000
- From Apr 2012 to the primary completion date, Dec 2050
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible
Other
- Unwillingness or unability to give written informed consent
- Participation in blinded RCTs or other studies incompatible with the NOR-DMARD study protocol
Who the study is looking for
- Age \>18 years
- Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, adult juvenile idiopathic arthritis, undifferentiated arthritis, or any other inflammatory arthritis
- Clinical indication to start a new treatment with a biological disease modifying anti-rheumatic drug or a kinase inhibitor
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vestre Viken HF Drammen Hospital Coordinator of this site? Confirm its status | Drammen | Norway | Completed |
| Førde Hospital Coordinator of this site? Confirm its status | Førde | Norway | Recruiting |
| Lillehammer Hospital for Rheumatic Diseases Coordinator of this site? Confirm its status | Lillehammer | Norway | Recruiting |
| Diakonhjemmet Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
| University Hospital of Northern Norway Coordinator of this site? Confirm its status | Tromsø | Norway | Recruiting |
| St Olavs Hospital Coordinator of this site? Confirm its status | Trondheim | Norway | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.